Introduction {#Sec1}
============

Aneurysmal subarachnoid hemorrhage (SAH) is a devastating disease with high morbidity and mortality. However, treatment remains insufficient, and drugs to improve patient outcomes are not well established. SAH is a complex pathology and involves vasospasm, acute or chronic hydrocephalus, systemic inflammation, and stressful treatments including surgical procedures. Many agents such as clazosentan, simvastatin, and magnesium sulfate have been assessed in large clinical studies; however, in clinical practice the effects have been disappointing \[[@CR1]--[@CR3]\].

Cerebrolysin (EVER Neuro Pharma™) is a neuropeptide preparation that mimics the action of endogenous neurotrophic factors in brain protection and recovery. It has been shown to be effective against excitotoxicity, inhibits free radical formation, has neurotrophic activity, improves cellular survival, and stimulates sprouting, synaptogenesis, and neurogenesis \[[@CR4]--[@CR9]\]. Several clinical studies have shown beneficial effects of Cerebrolysin in stroke, dementia, and traumatic brain injury \[[@CR10]--[@CR13]\]. A recent meta-analysis of nine randomized, double-blind, placebo-controlled stroke studies with 1879 patients confirmed the early beneficial effect of Cerebrolysin on global neurologic deficits \[[@CR14]\]. Recently, Cerebrolysin has been successfully tested for its neurorecovery potential in patients with moderate-to-severe strokes with treatment initiation in the acute and subacute phase \[[@CR11], [@CR15], [@CR16]\].

This study investigated potential benefits of Cerebrolysin in patients with aneurysmal SAH. To our knowledge, no such studies have been performed with Cerebrolysin before.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

We retrospectively reviewed medical charts from patients with SAH who underwent aneurysmal occlusion at our institution between January 2007 and December 2016. There was no significant change in surgical or endovascular instruments or treatment protocols during this period. The inclusion criteria were: (1) both sexes 18--85 years old, (2) having SAH within 48 h before admission, and (3) aneurysm obliterated with either clip or coil within 72 h after SAH. Exclusion criteria were early death within 72 h of admission, procedural complication, patients who discontinued Cerebrolysin treatment within 3 days, previous stroke or neurologic deficits, mental disability, psychologic disorders, or lost to follow-up within 3 months. All procedures performed in this study were in accordance with the ethical standards of the institution and with the 1964 Helsinki Declaration and its later amendments. For this type of study, formal consent is not required. This study is not registered as a clinical trial because of its retrospective design. This study was approved by the institutional review board at the author's institute (HYUH IRB 2017-10-007-001).

Treatment Groups {#Sec4}
----------------

Patients received Cerebrolysin treatment or standard care only (control group). Cerebrolysin was administered at daily doses of 30 ml for at least 3 days. Cerebrolysin was diluted in 1000 ml normal saline and was administered as a slow intravenous infusion over 24 h. Treatment was initiated within 48 h after SAH.

Data Collection {#Sec5}
---------------

Demographic information, radiologic findings, treatment, and clinical parameters were reviewed. These data included sex, age, hypertension, diabetes mellitus, treatment (clip or coil), and circulation (anterior or posterior). The Glasgow Coma Scale (GCS) and Hunt and Hess grade \[[@CR17]\] were used to record each patient's initial condition. The modified Fisher Scale, concomitant intracerebral hemorrhage (ICH), SAH sum score \[[@CR18]\], and intraventricular hemorrhage (IVH) sum score \[[@CR19]\] were recorded to evaluate initial radiologic findings. SAH sum score (0--30) was calculated as the mean of the Hijdra score, which is the sum of the amount of blood in ten cistern or fissure points (0--3 each). IVH sum score (0--12) was calculated as the mean Graeb score, which is the sum of the score for each ventricle (lateral ventricles, 0--4; third ventricle, 0--2; fourth ventricle, 0--2). Chronic hydrocephalus leading permanent shunt operation was reviewed. Angiographic vasospasm was defined as \> 50% decrease of the intracranial artery diameter by imaging or diagnostic angiography. Delayed cerebral ischemia was defined as the occurrence of focal neurologic impairment or a decrease of at least two points on the GCS score or one of its individual components lasting at least 1 h that could not be attributed to other causes \[[@CR20]\]. A blinded neuroradiologist at our institution recorded radiologic findings. The modified Rankin Scale (mRS) was used to evaluate clinical outcome 3 months after SAH \[[@CR21]\]. Mortality was defined as in-hospital death later than 72 h after SAH ictus.

Treatment of SAH Patients {#Sec6}
-------------------------

All patients had their aneurysm obliterated by either microscopic aneurysm neck clipping or endovascular coil embolization with or without stent assist. The therapy was chosen by the neurovascular team based on age, mental status, aneurysm location, size, and neck/dome presentation. All patients with posterior circulation including the vertebral and basilar arteries were treated with endovascular coil embolization. Blood pressure and glucose were managed strictly with close observation according to our institution's protocol. Patients in the Cerebrolysin group were not treated any differently from the control group except for Cerebrolysin.

Patient Group Classification {#Sec7}
----------------------------

Subgroup analyses were performed according to the severity of subarachnoid hemorrhage classified by the Hunt and Hess grade (good grade ≤ 2, *N* = 216; poor grade ≥ 3, *N* = 246) and treatment procedure (clipping, coiling).

Statistical Analysis {#Sec8}
--------------------

Non-parametric data were compared with chi-square and Fisher's exact tests. Parametric variables with a normal distribution were compared by independent *t* test and those without a normal distribution by Mann-Whitney U test. Descriptive summaries were reported as mean (± standard deviation) for continuous variables with normal distribution, median \[interquartile range (IQR)\] for continuous variables without normal distribution, and frequency (percentage) for categorical variables. All data were analyzed with R version 3.3.2 (<https://www.r-project.org/>; R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec9}
=======

Total Aneurysmal SAH Patients {#Sec10}
-----------------------------

Overall, 548 aneurysmal SAH patients were treated at our institution from 2007 to 2016; of these, 462 patients were included in this study. Patients were excluded because of early death within 72 h (*N* = 15), procedural complication (*N* = 8), previous neurologic deficits (*N* = 9), discontinuation of Cerebrolysin within 3 days (*N* = 19), and follow-up loss within 3 months (*N* = 35). Of 462 patients with SAH, 134 were included in the Cerebrolysin group and 328 in the control group. Demographic features, radiologic findings, and clinical outcomes are presented in Table [1](#Tab1){ref-type="table"}. Median treatment duration with Cerebrolysin was 13 \[10.0; 20.0\] days. Baseline parameters did not differ between groups except for the initial bicaudate index, which was higher in the control group (median; 17.6 vs. 15.7, *p* \< 0.001) and for the SAH sum score, which was higher in the Cerebrolysin group (median; 25.0 vs. 19.0, *p* = 0.002). Angiographic vasospasm occurred more often in the Cerebrolysin group than in the control group (41.0 vs. 30.5, *p* = 0.038). Three months after SAH, patients of both groups had a median mRS score of 2; the mortality rate was significantly higher in the control group (17.4%) than in the Cerebrolysin group (9.0%, *p* = 0.031).Table 1Demographic features, radiologic findings, and clinical outcomes in total SAH patientsControl (*N* = 328)Cerebrolysin (*N* = 134)*p* valueFemale221 (67.4%)84 (62.7%)0.391Age (years)55.0 \[47.0; 66.0\]56.0 \[48.0; 62.0\]0.876Operation type Clip232 (70.7%)96 (71.6%)0.934 Coil96 (29.3%)38 (28.4%)Circulation Anterior294 (89.6%)124 (92.5%)0.430 Posterior34 (10.4%)10 (7.5%)Hunt and Hess grade Grade 125 (7.6%)9 (6.7%)0.567 Grade 2126 (38.4%)56 (41.8%) Grade 393 (28.4%)34 (25.4%) Grade 479 (24.1%)30 (22.4%) Grade 55 (1.5%)5 (3.7%)Modified Fisher scale 131 (9.5%)12 (9.0%)0.096 25 (1.5%)5 (3.7%) 3119 (36.3%)35 (26.1%) 4173 (52.7%)82 (61.2%)GCS score13.0 \[9.5; 15.0\]14.0 \[8.0; 15.0\]0.964Concomitant ICH94 (28.7%)47 (35.1%)0.212Bicaudate index17.6 \[14.9; 20.2\]15.7 \[13.9; 18.3\]\< 0.001\*SAH sum score19.0 \[11.0; 26.0\]25.0 \[14.0; 28.0\]0.002\*IVH sum score1.0 \[0.0; 4.0\]1.0 \[0.0; 3.0\]0.375Smoking86 (26.2%)39 (29.1%)0.604Hypertension126 (38.4%)49 (36.6%)0.790Diabetes mellitus19 (5.8%)14 (10.4%)0.118Permanent shunt operation47 (14.3%)21 (15.7%)0.822Angiographic vasospasm100 (30.5%)55 (41.0%)0.038\*Delayed cerebral ischemia43 (13.1%)23 (17.2%)0.325Days of Cerebrolysin0.0 \[0.0; 0.0\]13.0 \[10.0; 20.0\]Length of stay (days)24.0 \[16.0; 47.0\]22.0 \[15.0; 46.0\]0.289mRS2.0 \[1.0; 5.0\]2.0 \[1.0; 5.0\]0.398Clinical outcome Favorable (mRS 0--2)181 (55.2%)70 (52.2%)0.636 Unfavorable (mRS 3--6)147 (44.8%)64 (47.8%)Mortality57 (17.4%)12 (9.0%)0.031\**SAH* subarachnoid hemorrhage, *GCS* Glasgow Coma Scale, *ICH* intracerebral hemorrhage, *IVH* intraventricular hemorrhage, *mRS* modified Rankin scale\*Indicates statistical significance (*p* \< 0.05)

Good-Grade SAH Patients (Hunt and Hess Grade ≤ 2) {#Sec11}
-------------------------------------------------

Of 216 patients with Hunt and Hess grade ≤ 2, 65 were included in the Cerebrolysin group and 151 in the control group. Demographic features, radiologic findings, and clinical outcomes are shown in Table [2](#Tab2){ref-type="table"}. Median treatment duration with Cerebrolysin was 12 \[9.0; 17.0\] days. Baseline parameters did not differ between groups except for the initial bicaudate index, which was significantly higher in the control group (median; 16.7 vs. 15.8, *p* = 0.043). Length of stay was significantly reduced by 4 days in the Cerebrolysin group, with statistical significance (22 vs. 18 median days, *p* = 0.015). Three months after SAH, patients of both groups had a median mRS score of 1; no significant group differences were reported for mortality.Table 2Demographic features, radiologic findings, and clinical outcomes in good-grade SAH patientsControl (*N* = 151)Cerebrolysin (*N* = 65)*p* valueFemale104 (68.9%)39 (60.0%)0.268Age53.0 \[44.0; 64.0\]55.0 \[47.0; 59.0\]0.581Operation type Clip103 (68.2%)45 (69.2%)1.000 Coil48 (31.8%)20 (30.8%)Circulation Anterior141 (93.4%)61 (93.8%)1.000 Posterior10 (6.6%)4 (6.2%)Hunt and Hess grade Grade 125 (16.6%)9 (13.8%)0.766 Grade 2126 (83.4%)56 (86.2%)Modified Fisher scale 127 (17.9%)9 (13.8%)0.357 22 (1.3%)2 (3.1%) 366 (43.7%)23 (35.4%) 456 (37.1%)31 (47.7%)GCS score15.0 \[15.0; 15.0\]15.0 \[15.0; 15.0\]0.761Concomitant ICH23 (15.2%)14 (21.5%)0.352Bicaudate index16.7 \[14.5; 19.4\]15.8 \[14.1; 17.7\]0.043\*SAH sum score14.0 \[8.0; 22.0\]17.0 \[10.0; 27.0\]0.051IVH sum score0.0 \[0.0; 1.0\]1.0 \[0.0; 2.0\]0.106Smoking40 (26.5%)21 (32.3%)0.480Hypertension46 (30.5%)24 (36.9%)0.440Diabetes mellitus5 (3.3%)7 (10.8%)0.061Permanent shunt15 (9.9%)5 (7.7%)0.791Angiographic vasospasm49 (32.5%)19 (29.2%)0.758Delayed cerebral ischemia18 (11.9%)7 (10.8%)0.991Days of Cerebrolysin0.0 \[0.0; 0.0\]12.0 \[9.0; 17.0\]Length of stay (days)22.0 \[17.0; 34.0\]18.0 \[15.0; 26.0\]0.015\*mRS1.0 \[1.0; 2.0\]1.0 \[0.0; 2.0\]0.145Clinical outcome Favorable (mRS 0--2)119 (78.8%)50 (76.9%)0.898 Unfavorable (mRS 3--6)32 (21.2%)15 (23.1%)Mortality12 (7.9%)6 (9.2%)0.964*SAH* subarachnoid hemorrhage, *GCS* Glasgow Coma Scale, *ICH* intracerebral hemorrhage, *IVH* intraventricular hemorrhage, *mRS* modified Rankin Scale\*Indicates statistical significance (*p*  \< 0.05)

Poor-Grade SAH Patients (Hunt and Hess Grade ≥ 3) {#Sec12}
-------------------------------------------------

Of 246 patients with Hunt and Hess grade ≥ 3, 69 were included in the Cerebrolysin group and 177 in the control group. Demographic features, radiologic findings, and clinical outcomes are shown in Table [3](#Tab3){ref-type="table"}. Median treatment duration with Cerebrolysin was 14 \[12.0; 21.0\] days. Baseline parameters did not differ between groups except for the initial bicaudate index, which was significantly higher in the control group (median; 18.1 vs. 15.7, *p* = 0.001) and for the SAH sum score, which was significantly higher in the Cerebrolysin group (median; 27.0 vs. 25.0, *p* = 0.001). Angiographic vasospasm occurred more often in the Cerebrolysin group compared with the control group (52.2% vs. 28.8%, *p* = 0.001). Three months after SAH, patients of both groups had a median mRS score of 4; the mortality rate was significantly higher in the control group (25.4%) than in the Cerebrolysin group (8.7%, *p* = 0.006).Table 3Demographic features, radiologic findings, and clinical outcomes in poor-grade SAH patientsControl (*N* = 177)Cerebrolysin (*N* = 69)*p* valueFemale sex117 (66.1%)45 (65.2%)1.000Age56.0 \[49.0; 68.0\]56.0 \[50.0; 65.0\]0.599Operation type Clip129 (72.9%)51 (73.9%)0.997 Coil48 (27.1%)18 (26.1%)Circulation Anterior153 (86.4%)63 (91.3%)0.406 Posterior24 (13.6%)6 (8.7%)Hunt and Hess grade Grade 393 (52.5%)34 (49.3%)0.286 Grade 479 (44.6%)30 (43.5%) Grade 55 (2.8%)5 (7.2%)Modified Fisher scale 14 (2.3%)3 (4.3%)0.133 23 (1.7%)3 (4.3%) 353 (29.9%)12 (17.4%) 4117 (66.1%)51 (73.9%)GCS score11.0 \[6.0; 13.0\]8.0 \[6.0; 13.0\]0.447Concomitant ICH71 (40.1%)33 (47.8%)0.339Bicaudate index18.1 \[15.3; 21.3\]15.7 \[13.7; 18.8\]0.001\*SAH sum score25.0 \[14.0; 27.0\]27.0 \[23.0; 29.0\]0.001\*IVH sum score2.0 \[0.0; 5.0\]2.0 \[1.0; 4.0\]0.994Smoking46 (26.0%)18 (26.1%)1.000Hypertension80 (45.2%)25 (36.2%)0.257Diabetes mellitus14 (7.9%)7 (10.1%)0.757Permanent shunt32 (18.1%)16 (23.2%)0.466Angiographic vasospasm51 (28.8%)36 (52.2%)0.001Delayed cerebral ischemia25 (14.1%)16 (23.2%)0.128Days of Cerebrolysin0.0 \[0.0; 0.0\]14.0 \[12.0; 21.0\]Length of stay (days)30.0 \[15.0; 67.0\]33.0 \[16.0; 70.0\]0.547mRS4.0 \[2.0; 6.0\]4.0 \[2.0; 5.0\]0.525Clinical outcome Favorable (mRS 0--2)62 (35.0%)20 (29.0%)0.452 Unfavorable (mRS 3--6)115 (65.0%)49 (71.0%)Mortality45 (25.4%)6 (8.7%)0.006\**SAH* subarachnoid hemorrhage, *GCS* Glasgow Coma Scale, *ICH* intracerebral hemorrhage, *IVH* intraventricular hemorrhage, *mRS* modified Rankin Scale\*Indicates statistical significance (*p*  \< 0.05)

Clip and Coil Patients {#Sec13}
----------------------

Of 462 patients, 328 (71.0%) had microsurgical aneurysm neck clipping and 134 (29.0%) had endovascular coil embolization. Demographic features, radiologic findings, and clinical outcomes are shown in Table [4](#Tab4){ref-type="table"}. In clip patients, the initial bicaudate index was significantly higher in the control group (median; 17.5 vs. 15.5, *p* \< 0.001) and the SAH sum score was significantly higher in the Cerebrolysin group (median; 25.0 vs. 19.0, *p* = 0.007). Angiographic vasospasm developed more often in the Cerebrolysin group (33.6% vs. 47.9%, *p* = 0.021), and delayed cerebral ischemia was not statistically different between groups (12.5% vs. 20.8%, *p* = 0.079). Three months after SAH, the mortality rate was significantly lower in the Cerebrolysin group (median; 7.3% vs. 18.5%, *p* = 0.016). No significant group differences were observed in the mRS. Coil patients did not differ in baseline characteristics or outcome parameters.Table 4Demographic features, radiologic findings, and clinical outcomes by operation type (clip versus coil)Clip (*N* = 328)Coil (*N* = 134)Control (*N* = 232)Cerebrolysin (*N* = 96)*p*Control (*N* = 96)Cerebrolysin (*N* = 38)*p*Female155 (66.8%)59 (61.5%)0.42466 (68.8%)25 (65.8%)0.900Age55.0 \[48.0; 66.0\]55.0 \[49.0; 61.5\]0.60155.1 ± 13.356.4 ± 14.40.639Circulation Anterior232 (100.0%)96 (100.0%)62 (64.6%)28 (73.7%)0.420 Posterior0 (0.0%)0 (0.0%)34 (35.4%)10 (26.3%)Hunt and Hess grade3.0 \[2.0; 4.0\]3.0 \[2.0; 4.0\]0.7782.5 \[2.0; 3.0\]2.0 \[2.0; 3.0\]0.832Modified Fisher scale 1 and 222 (9.5%)11 (11.5%)0.73414 (14.6%)6 (15.8%)1.000 3 and 4210 (90.5%)85 (88.5%)82 (85.4%)32 (84.2%)GCS score13.0 \[8.0; 15.0\]13.0 \[7.0; 15.0\]0.84314.0 \[12.0; 15.0\]14.0 \[9.0; 15.0\]0.872Bicaudate index17.5 ± 3.915.5 ± 3.2\< 0.001\*17.8 \[15.1; 20.8\]16.9 \[14.8; 21.8\]0.706SAH sum score19.0 \[12.0; 26.0\]25.0 \[14.0; 28.0\]0.007\*17.5 \[8.5; 26.0\]23.0 \[11.0; 28.0\]0.102IVH sum score1.0 \[0.0; 4.0\]1.0 \[0.0; 2.0\]0.9891.0 \[0.0; 4.0\]2.0 \[0.0; 6.0\]0.099Concomitant ICH81 (34.9%)41 (42.7%)0.22913 (13.5%)6 (15.8%)0.951Smoking66 (28.4%)20 (20.8%)0.19729 (30.2%)10 (26.3%)0.813Hypertension82 (35.3%)37 (38.5%)0.67344 (45.8%)12 (31.6%)0.189Diabetes mellitus16 (6.9%)11 (11.5%)0.2513 (3.1%)3 (7.9%)0.459Permanent shunt38 (16.4%)17 (17.7%)0.8969 (9.4%)4 (10.5%)1.000Angiographic vasospasm78 (33.6%)46 (47.9%)0.021\*22 (22.9%)9 (23.7%)1.000Delayed cerebral ischemia29 (12.5%)20 (20.8%)0.07914 (14.6%)3 (7.9%)0.447Days of Cerebrolysin14.0 \[11.0; 20.5\]12.0 \[8.0; 16.0\]Length of stay (days)27.0 \[17.0; 60.0\]23.0 \[16.0; 50.5\]0.37220.0 \[15.0; 33.5\]18.0 \[14.0; 32.0\]0.407mRS score2.0 \[1.0; 5.0\]3.0 \[1.0; 5.0\]0.2391.0 \[1.0; 4.0\]2.0 \[1.0; 4.0\]0.743Clinical outcome Favorable (mRS 0--2)119 (51.3%)46 (47.9%)0.66362 (64.6%)24 (63.2%)1.000 Unfavorable (mRS 3--6)113 (48.7%)50 (52.1%)34 (35.4%)14 (36.8%)Mortality43 (18.5%)7 (7.3%)0.016\*14 (14.6%)5 (13.2%)1.000*SAH* subarachnoid hemorrhage, *GCS* Glasgow Coma Scale, *ICH* intracerebral hemorrhage, *IVH* intraventricular hemorrhage, *mRS* modified Rankin Scale\*Indicates statistical significance (*p*  \< 0.05)

Safety {#Sec14}
------

The median treatment duration with Cerebrolysin was 13.0 days. Table [5](#Tab5){ref-type="table"} shows the rate of adverse events with severe intensity for both groups. The most common adverse event was pneumonia followed by urinary tract infection, acute renal failure, and myocardial infarction. There was no significant difference between the two groups.Table 5Comparison of adverse events of severe intensity between control and Cerebrolysin groupsControl (*N* = 328)Cerebrolysin (*N* = 134)*p* valuePneumonia29 (8.84%)12 (8.96%)1.000Urinary tract infection18 (5.49%)8 (5.97%)0.986CSF infection3 (0.91%)2 (1.49%)0.630Acute renal failure17 (5.18%)4 (2.99%)0.434Pulmonary embolism5 (1.52%)1 (0.75%)0.678Acute cholecystitis0 (0.00%)1 (0.75%)Myocardial infarction14 (4.29%)5 (3.73%)1.000Severe adverse event82 (25.0%)31 (23.1%)0.761*CSF* cerebrospinal fluid

Discussion {#Sec15}
==========

The current study showed excellent outcomes in both study groups and a similar low mortality rate in SAH patients with good grade according to Hunt and Hess. In contrast, in patients with poor grade, the mortality rate was significantly higher in the control group (25.4% versus 8.7%) than in Cerebrolysin-treated patients. These findings are reminiscent of previous studies showing beneficial effects of Cerebrolysin especially in more severely affected patients of different brain pathologies. The results of the CASTA trial reported a reduced mortality rate in more severely affected ischemic stroke patients treated with Cerebrolysin \[[@CR22]\]. Similarly, Khalili et al. showed that Cerebrolysin is associated with improved functional recovery, decreased mortality rate, and better outcome in patients with severe disability after traumatic brain injury \[[@CR23]\].

Of note, our study showed a lower mortality rate in the Cerebrolysin group in patients with microsurgical clipping but not in patients with endovascular coiling. This might be because surgical clipping was more frequently performed in patients with higher Hunt and Hess grades and in patients with concomitant ICH because of the advantage of evacuating the hematoma simultaneously. Although angiographic vasospasm and delayed cerebral ischemia occurred more often in poor-grade SAH patients treated with Cerebrolysin, the mortality rate was higher in the control group.

Inhibition of brain edema seems to be a key mechanism for lowering the mortality rate in the acute phase after SAH. Maintaining the blood-brain barrier integrity can reduce vasogenic edema, and anti-inflammatory effects contribute to decreased cytotoxic edema \[[@CR24]\]. An intracranial hemorrhage rat model showed that Cerebrolysin inhibited brain edema and the inflammatory response and protected the integrity of the blood-brain barrier \[[@CR10]\]. In a mouse stroke model study, Cerebrolysin inhibited the effect of proinflammatory mediators such as TNF-α, IL-1β, IL-6, and NF-κB \[[@CR21], [@CR22]\]. Unfortunately, we could not assess the effect of Cerebrolysin on brain edema formation in the current study, but it would be interesting to address this in future studies.

One of the limitations of this study was the retrospective design. Accordingly, data from medical records were limited and did not allow precise matching of patients in terms of baseline characteristics. Furthermore, treatment with Cerebrolysin was limited to the acute phase of SAH, and treatment duration varied between 8 and 21 days. For efficacy assessment, no data were available regarding functional disability or cognitive or neuropsychologic outcome. Due to the exclusion of patients who died within 72 h (*N* = 15), the mortality rate might have been slightly underestimated. However, to our knowledge, this is the largest study that evaluated the effects of Cerebrolysin in aneurysmal SAH patients. Despite the limited level of evidence of this retrospective study, we think that these results are promising and could provide guidance for future randomized studies evaluating the effect of Cerebrolysin on SAH patients.

Conclusions {#Sec16}
===========

Hemorrhagic stroke including aneurysmal SAH is a devastating disease causing severe bain damage. This study suggests a potential benefit of Cerebrolysin to reduce the mortality rate in patients with aneurysmal SAH, which should be further evaluated in clinical studies.
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